Impact of symptomatic multiple sclerosis therapy on pregnancy outcome
Multiple Sclerosis Journal · 2024
DOI: 10.1177/13524585241293363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Laura Witt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, St. Josef-Hospital, Katholisches Klinikum Bochum, Ruhr-University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Pregnancy Outcome, Pregnancy Complications, Multiple Sclerosis, Registries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Biogen, Roche, Sanofi Genzyme.
Abstract (Originalsprache)
Background
Information on symptomatic therapy (ST) use in women of childbearing age with multiple sclerosis is sparse, and data on the impact of ST pregnancy exposure on pregnancy outcome are lacking.
Objective
To investigate (1) ST use patterns pre-conception, during pregnancy and postpartum and (2) pregnancy outcomes.
Methods
Pregnancy data from the German Multiple Sclerosis and Pregnancy Registry were analyzed for the ST use from pre-conception to postpartum. Pregnancy outcomes were compared between ST-exposed ( n = 282) and matched (disease modifying therapy and age) ST-naive (n = 536) pregnancies.
Results
Of 2,449 pregnancies, 1,053 (43.0%) received ST anytime between pre-conception and postpartum, 282 (11.5%) at pre-conception and during pregnancy. The most commonly used drug classes were antidepressants (24.8%), analgetics (31.0%), and anticonvulsives (8.7%). Exposure to ST during pregnancy did not result in an increased incidence of adverse pregnancy outcomes, major congenital abnormalities, or pregnancy complications.
Conclusion
Nearly 50% of women used ST between pre-conception and postpartum, but only 12% pre-conception and during pregnancy. ST use during pregnancy did not adversely affect pregnancy outcomes in our cohort. More data are needed to analyze the effect of ST on pregnancy and fetal outcomes stratified by drug to improve recommendations for ST use in family planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, St. Josef-Hospital, Katholisches Klinikum Bochum, Ruhr-University Bochum, Bochum, Germany.
- Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
- Neurologische Klinik, St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum.
ORCID-Profile: Laura Witt, Nadine Bast
Förderung
- Biogen
- Roche
- Sanofi Genzyme
- Hexal AG
- Innovation Fund of the Federal Joint Committee
- Merck
- Teva Pharmaceutical Industries
- Novartis
Zitieren
APA
Witt, L., Haben, S., Dost-Kovalsky, K., Friedmann, N., Bast, N., Oganowski, T., Gold, R., Thiel, S., & Hellwig, K. (2024). Impact of symptomatic multiple sclerosis therapy on pregnancy outcome. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241293363
Vancouver
Witt L, Haben S, Dost-Kovalsky K, Friedmann N, Bast N, Oganowski T, et al. Impact of symptomatic multiple sclerosis therapy on pregnancy outcome. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241293363
BibTeX
@article{Witt2024,
author = {Witt, Laura and Haben, Sabrina and Dost-Kovalsky, Karen and Friedmann, Natalia and Bast, Nadine and Oganowski, Theresa and Gold, Ralf and Thiel, Sandra and Hellwig, Kerstin},
title = {Impact of symptomatic multiple sclerosis therapy on pregnancy outcome},
journal = {Multiple Sclerosis Journal},
year = {2024},
doi = {10.1177/13524585241293363}
}
EUVIMED